Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali

Kayentao, Kassoum; Ongoïba, Aïssata; Preston, Anne C; Healy, Sara A.; Doumbo, Safiatou; Doumtabé, Didier; Traoré, A.; Traore, Hamadi; Djiguiba, Adama; Li, Shanping; Peterson, Mary; Telscher, Shinyi; Idris, Azza H.; Kisalu, Neville K.; Carlton, Kevin; Serebryannyy, Leonid A.; Narpala, Sandeep; McDermott, Adrian B.; Gaudinski, Martin R.; Traore, Siriman; Cisse, Hamidou; Keita, Mamadou; Skinner, Jeff; Hu, Zonghui; Zeguimé, Amatigué; Ouattara, Adama; Doucoure, M'Bouye; Dolo, Amagana; Djimdé, Abdoulaye; Traoré, Boubacar; Seder, Robert A.; Crompton, Peter D.

doi:10.1056/nejmoa2206966

Cited by 58 publications

(42 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Neue Entwicklungen: Monoklonale Antikörper (Mak) Gegen Malariaunclassified

“…Eine kürzlich publizierte Phase-II-Studie zeigte auch das Potenzial dieser Technologie zur Prävention der Malaria in Endemiegebieten auf. Eine einmalige Gabe des MAb führte bei Erwachsenen in Mali zu einer über 80-prozentigen Schutzrate über 6 Monate[47].Weitere Folgestudien unter "Real-World-Bedingungen" sind notwendig, um dieses Konzept weiter zu untersuchen, bevor eine mögliche Marktreife konstatiert werden kann.InteressenkonfliktSilja Bühler erhielt Honorare für Vortragstätigkeiten für Sanofi-Aventis und Bavarian Nordic. Die übrigen Autorinnen und Autoren geben an, dass kein Interessenkonflikt besteht.…”

unclassified

See 1 more Smart Citation

Empfehlungen zur Malariaprophylaxe

Rothe,

Veit,

Bühler

et al. 2023

Flugmedizin · Tropenmedizin · Reisemedizin - FTR

View full text Add to dashboard Cite

EinleitungDer Ständige Ausschuss Reisemedizin (StAR) der Deutschen Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e. V. (DTG) erarbeitet jährlich Empfehlungen zu Reiseimpfungen und zur Malariaprophylaxe. Der StAR setzt sich aus Expertinnen und Experten der großen Tropeninstitute und tropenmedizinischen Abteilungen, des Auswärtigen Amts, der Bundeswehr, der Gesellschaft für Internationale Zusammenarbeit (GIZ), der Arbeitsmedizin, der Flugmedizin und maritimen Medizin, der Deutschen Gesellschaft für Reisemedizin (DFR) sowie des niedergelassenen Bereichs zusammen. Der StAR arbeitet bereits seit vielen Jahren eng mit dem schweizerischen Expertenkomitee für Reisemedizin (EKRM) zusammen. Neu und sehr erfreulich ist, dass seit 2022 nun auch Experten aus Belgien und den Niederlanden sich an den Empfehlungen beteiligen. Ziel ist es, in der Zukunft eine Harmo nisierung der Empfehlungen zur Malariaprophylaxe im europäischen Raum zu erreichen.Die im Folgenden zur besseren Lesbarkeit gewählte männliche Form bezieht sich immer zugleich auf weibliche, männliche und diverse Personen.

show abstract

Section: Neue Entwicklungen: Monoklonale Antikörper (Mak) Gegen Malariaunclassified

unclassified

Empfehlungen zur Malariaprophylaxe

Rothe,

Veit,

Bühler

et al. 2023

Flugmedizin · Tropenmedizin · Reisemedizin - FTR

View full text Add to dashboard Cite

show abstract

“…Developing highly effective tools against Plasmodium falciparum , the parasite that causes the most severe form of malaria, is a long-sought global health priority (WHO, 2021). Encouraging progress has been made recently in the development of vaccines and monoclonal antibodies (mAbs) that target P. falciparum sporozoites, the parasite stage transmitted by Anopheles mosquitoes to initiate infection in the human host (Datoo et al, 2022; Kayentao et al, 2022; Mwakingwe-Omari et al, 2021; Wu et al, 2022). However, the protection provided by these interventions does not extend to the subsequent disease-causing blood stage of infection due to antigenic differences between the two parasite stages.…”

Section: Introductionmentioning

confidence: 99%

Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5

Wang,

Cooper,

Farrell

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Plasmodium falciparumRH5 is the most advanced blood-stage malaria vaccine candidate and is under evaluation for efficacy in endemic regions, emphasizing the need to study the underlying antibody response to RH5 during natural infection. Here, we found that RH5-reactive B cells were rare in malaria-exposed individuals despite repeated infections over multiple years. RH5-specific monoclonal antibodies isolated from these individuals were extensively mutated but mostly targeted non-neutralizing epitopes, in contrast to antibodies from RH5-vaccinated, malaria-naive individuals. However, infection-derived MAD8-151 and MAD8-502 were among the most potent neutralizers out of 186 antibodies isolated from both cohorts and target the same epitopes as the most effective vaccine-induced antibodies. Binding to basigin receptor-proximal epitopes was the primary factor governing the potency of RH5-specific antibodies from both natural infection and vaccination, followed by the strength of binding. These results indicate a clear strategy for the development of next-generation RH5 vaccines for use in malaria-endemic regions.

show abstract

“…The emergence of biological threats and other challenges for elimination, such as mutations in parasite histidine-rich protein 2 and protein 3 genes causing false-negative rapid diagnostic tests, insecticide resistance in mosquito vectors, the spread of invasive Anopheles stephensi , and resistance to antimalarial drugs, highlight the urgent need for research on host–parasite interactions and the development of new tools. A recent Phase II trial on CIS43LS, a monoclonal antibody against the junctional epitope on the Pf CSP, has been reported to offer 88.2% protective efficacy against P. falciparum infection in adults over a 6-month malaria period in Mali, suggesting human monoclonal antibodies might be a new approach in conferring immunity, but only for a defined period …”

Section: Introductionmentioning

confidence: 99%

Advancements and Challenges in Developing Malaria Vaccines: Targeting Multiple Stages of the Parasite Life Cycle

Rajneesh,

Tiwari,

Singh

et al. 2023

ACS Infect. Dis.

View full text Add to dashboard Cite

Malaria, caused by Plasmodium species, remains a major global health concern, causing millions of deaths annually. While the introduction of the RTS,S vaccine has shown promise, there is a pressing need for more effective vaccines due to the emergence of drug-resistant parasites and insecticide-resistant vectors. However, the complex life cycle and genetic diversity of the parasite, technical obstacles, limited funding, and the impact of the 2019 pandemic have hindered progress in malaria vaccine development. This review focuses on advancements in malaria vaccine development, particularly the ongoing clinical trials targeting antigens from different stages of the Plasmodium life cycle. Additionally, we discuss the rationale, strategies, and challenges associated with vaccine design, aiming to enhance the immune response and protective efficacy of vaccine candidates. A cost-effective and multistage vaccine could hold the key to controlling and eradicating malaria.

show abstract

Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali

Cited by 58 publications

References 22 publications

Empfehlungen zur Malariaprophylaxe

Empfehlungen zur Malariaprophylaxe

Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5

Advancements and Challenges in Developing Malaria Vaccines: Targeting Multiple Stages of the Parasite Life Cycle

Contact Info

Product

Resources

About